Walorski, Phillips Lead Bipartisan Bill To Spur Innovation, Protect Vulnerable Startups

Thursday, June 3, 2021

Walorski, Phillips Lead Bipartisan Bill To Spur Innovation, Protect Vulnerable Startups

IGNITE American Innovation Act Would Provide Tax Relief to Medical Device Startups, Other Tech Innovators

MISHAWAKA, Ind. – U.S. Reps. Jackie Walorski (R-Ind.) and Dean Phillips (D-Minn.) today introduced the IGNITE American Innovation Act, a bipartisan bill to provide relief for startup businesses that were ineligible for other types of aid passed by Congress in response to the COVID-19 pandemic.

“High-tech innovators like medical device manufacturers in northern Indiana will be vital to rebuilding our economy after the COVID-19 pandemic,” Congresswoman Walorski said. “Providing tax relief to cutting-edge startups is a commonsense way to ensure they can continue to develop life-saving technologies, discover treatments and cures, and create good jobs. I’m grateful to work across the aisle to boost small and mid-size businesses and drive innovation when we need it more than ever.”

“The Great Recession did severe and lasting damage to American entrepreneurship,” Congressman Phillips said. “We cannot and must not allow the COVID-19 pandemic to do the same. This bipartisan bill will deliver long-overdue relief to our nation’s innovators and ensure that they continue to develop the lifesaving and game-changing technologies our economy and communities rely on.”

BACKGROUND

U.S. startups are some of the most innovative firms in the world, and for the past year many have been working on products to fight the COVID-19 crisis and future pandemic threats. Walorski’s IGNITE American Innovation Act will allow small and mid-size businesses left out of the CARES Act to access fast and efficient capital, so that they can continue that important work and accelerate our nation’s recovery.

Specifically, the IGNITE American Innovation Act would:

  • Allow growth companies to monetize up to $25 million of accumulated net operating losses (NOLs) and R&D credits; and
  • Double the value of R&D credits generated by research into products to prevent, diagnose, or treat COVID-19 and future pandemic threats.

The bill is already being praised by a coalition of advocates for tech startups:

  • Mark Leahey, President and CEO of the Medical Device Manufacturers Association (MDMA): “MDMA thanks Congressman Phillips and Congresswoman Walorski for their ongoing bipartisan leadership to provide support and resources for medical technology innovators who are dedicated to develop the cures, diagnostics and therapies of tomorrow. As the medtech ecosystem continues to confront COVID-19 and the numerous other challenges facing patients and physicians, the ‘IGNITE Act’ would provide some of the critical liquidity that is needed to do so.”
  • Peter Chandler, TechNet’s VP of Federal Policy & Government Relations: “Startups are the lifeblood of our economy. They have the highest potential for job growth and create jobs at faster rates than older companies. As we begin the next phase of our post-pandemic recovery, startups will play a critical role in creating jobs and growing our economy. The IGNITE Act would provide an immediate boost to startups, giving them the liquidity needed to hire talent and invest in innovation. This bill will help boost our economic recovery and strengthen America’s position as a global leader.”
  • Bobby Franklin, President, National Venture Capital Association:IGNITE will accelerate investments in startup ecosystems across the country to power the jobs and economy of the future. This bipartisan legislation will provide immediate liquidity to our most innovative companies that must be used to finance job creation, R&D, or facility construction, creating more economic opportunity, and boosting American competitiveness.”
  • John Dearie, President, Center for American Entrepreneurship: “CAE applauds the re-introduction of the IGNITE American Innovation Act and thanks Reps. Dean Phillips (D-MN) and Jackie Walorski (R-IN) for their continued leadership on this critical issue. In addition to its devastating toll in human lives, the Covid-19 pandemic inflicted a devastating blow to the U.S. economy, forcing the permanent closure of hundreds of thousands of businesses and destroying millions of jobs.  As the nation emerges from the crisis, accelerating economic growth and job creation is the top domestic policy priority.  Innovative startups will play a major role in this effort.  Repeated research has demonstrated that startups account for a disproportionate share of the innovations that drive economic growth and job creation.  But to succeed, startups need capital.  The bipartisan IGNITE American Innovation Act is critical to ensuring that the nation’s startups have the capital they need to drive the post-Covid recovery.  Because most startups remain “pre-revenue” for a number of years after they launch, they have no income tax obligation against which to write-off valuable tax assets like net operating losses and research and development tax credits – which existing businesses are able to monetize by reducing their income tax liability.  The IGNITE American Innovation Act would amend the tax code to allow high-growth startups to monetize up to $25 million of these tax assets, providing additional liquidity to fuel their success.  The Act is an essential element of America’s strategy of innovation-driven economic revitalization.”
  • Jennifer Grundy Young, CEO, Technology Councils of North America: “In many cases startups are financially fragile and are assuming significant risk – risk that could result in solving critical problems. It is important to have policies, like the IGNITE Act, in place to ensure start-up, growing companies are well capitalized to advance important research and development.  We look forward to working with congressional members to advance this important legislation.”
  • Cameron Arterton, Biotechnology Innovation Organization’s Vice President, Tax Policy: “BIO is pleased to support the reintroduction of the IGNITE American Innovation Act which will provide immediate liquidity to our emerging biotechnology companies and be used to support R&D, innovation, and job creation. We want to thank the sponsors for their attention and work on this important piece of legislation.”
  • Scott Whitaker, President and CEO, Advanced Medical Technology Association: “Investment in innovation is investment in a better future for all of us. But investment in innovation can be difficult, especially for small and start-up companies and especially in the wake of the COVID-19 pandemic. Smart policy, like the IGNITE American Innovation Act, can help ease entrepreneurs’ path to success, which, in turn, can help speed people’s access to that success. For medtech, that means access to life-saving treatments and cures. We’re proud to join the American Startups and Job Growth Coalition in urging Congress to pass IGNITE.”

Walorski represents the 2nd Congressional District of Indiana, serving as a member of the House Ways and Means Committee and the Ranking Member of the House Ethics Committee.

###

Get News & Updates